Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, January 7, 2019
[ Mon, Jan 07th 2019
] - WOPRAI
[ Mon, Jan 07th 2019
] - WOPRAI
[ Mon, Jan 07th 2019
] - WOPRAI
[ Mon, Jan 07th 2019
] - WOPRAI
[ Mon, Jan 07th 2019
] - WOPRAI
Fri, January 4, 2019
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
[ Fri, Jan 04th 2019
] - WOPRAI
Robyn Karnauskas Maintained (VRTX) at Strong Buy with Decreased Target to $205 on, Jan 4th, 2019
Robyn Karnauskas of Citigroup, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Decreased Target from $206 to $205 on, Jan 4th, 2019.
Robyn has made no other calls on VRTX in the last 4 months.
There are 4 other peers that have a rating on VRTX. Out of the 4 peers that are also analyzing VRTX, 1 agrees with Robyn's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Christopher Raymond of "Raymond James" Downgraded from Buy to Hold on, Wednesday, January 2nd, 2019
These are the ratings of the 3 analyists that currently disagree with Robyn
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $210 on, Wednesday, December 19th, 2018
- Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Held Target at $220 on, Friday, October 26th, 2018
- Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $192 on, Thursday, October 25th, 2018
